ClinicalTrials.gg
Not yet recruitingNCT03644641Updated May 10, 2024

The Influence of Prone Position for Spinal Surgery on Visual Acuity

An interventional study of Desflurane Group and Propofol Group in Vision; Disorder, Loss, sponsored by University Hospital Hradec Kralove. Not yet recruiting at 1 site in Czechia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by University Hospital Hradec Kralove · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Vision Disorders with a site in Czechia — 3 open to participants now, 3 under way, none of them phase 3. Vision Disorders · Czechia.

Planned enrollment
14th of 15
60 · median 450
Started
2025
the only one that year
No phase
2 of 16
2 open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
University Hospital Hradec Kralove

Among the 16 studies in Vision Disorders with a site in Czechia, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 6th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

3 of the 16 studies in Vision Disorders with a site in Czechia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vision Disorders with a site in Czechia, or all of them as a file.
02

Study summary

This study investigated the effect of desflurane and propofol anesthesia on visual acuity in patients in prone position for spinal surgery. Many trials have investigated the effects of different anesthetic agents on intraocular pressure, propofol may reduce intraocular pressure more than other intravenous anesthetics.

Read the detailed description

Perioperative increase in intraocular pressure can be caused by prone positioning. In addition to surgical factors, patients with glaucoma, uncontrolled hypertension, arthrosclerosis, and morbid obesity are at risk for potentially damaging optic nerve and loss of optic nerve function. Some studies found that intraocular pressure values were significantly lower in patients undergoing propofol total intravenous anesthesia than in patients undergoing desflurane anesthesia during intraoperative positional changes. Pronounced vasodilatation caused by desflurane might produced hyperaemia with higher intraocular pressure. Hemodynamic response to prone position measured by near-infrared spectroscopy (NIRS) on the prefrontal cortex could determine changes caused by prone position.

03

Conditions studied

  • Vision; Disorder, Loss

Browse trials for

Keywords

  • Desflurane
  • Near-infrared spectroscopy
  • Propofol
  • Spinal surgery
  • Prone position
  • Visual acuity
  • Visual loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glasgow Coma scale 15
  • (ASA) Physical Status Classification System I-III
  • spinal surgery in duration less than 3 hours
  • sinus rhythm

Exclusion criteria

Exclusion Criteria:

  • postoperative artificial ventilation
  • serious neurological disease
  • lung disease with hypercapnia
  • propofol allergy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Desflurane Group

    Induction and anesthesia will be held by using desflurane

    Procedure: Desflurane Group

  • Experimental
    Propofol Group

    Induction and anesthesia will be held by using target-control anesthesia with propofol

    Procedure: Propofol Group

Interventions

  • ProcedureDesflurane Group

    General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).

  • ProcedurePropofol Group

    General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).

06

What researchers measure

Primary outcomes

  1. Visual injury

    worsening of test for visual acuity (Rodenstock)

    Time frame: 48 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Nov 2028, 36 months later.

Of 84 non-industry interventional studies with no phase under Vision Disorders, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 51. This study's planned 36 months is above that.

Counting every sponsor, half of 94 studies reached it within 24 months; a quarter within 6 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2018
First posted
Aug 23, 2018
StartEst.
Nov 28, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 30, 2029
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03644641
Lead sponsor
University Hospital Hradec Kralove
Responsible party
Dostalova Vlasta, MD, PhD (Principal Investigator, University Hospital Hradec Kralove) — Principal investigator
First posted
Aug 23, 2018
Start date
Nov 28, 2025 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
May 10, 2024

Study contacts

Vlasta Dostalova, MD, Ph.D.
Contact
vlasta.dostalova@fnhk.cz
+420777883571
Pavel Dostal, MD, Ph.D.
Contact
pavel.dostal@fnhk.cz
+420495833218
Pavel Dostal, MD, Ph.D.
study director · Hradec Kralove, Czechia 50005

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion